2496 Stock Overview
A biotechnology company, develops bispecific antibody-based therapies for the treatment of cancer, cancer-related complications, and age-related eye diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Wuhan YZY Biopharma Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$7.94 |
| 52 Week High | HK$8.96 |
| 52 Week Low | HK$3.65 |
| Beta | 0 |
| 1 Month Change | 101.01% |
| 3 Month Change | 14.24% |
| 1 Year Change | -8.21% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -50.38% |
Recent News & Updates
Shareholder Returns
| 2496 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 28.3% | -3.2% | -2.4% |
| 1Y | -8.2% | -10.2% | 16.2% |
Return vs Industry: 2496 matched the Hong Kong Biotechs industry which returned -8.4% over the past year.
Return vs Market: 2496 underperformed the Hong Kong Market which returned 19.4% over the past year.
Price Volatility
| 2496 volatility | |
|---|---|
| 2496 Average Weekly Movement | 15.8% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 8.2% |
| 10% most volatile stocks in HK Market | 16.5% |
| 10% least volatile stocks in HK Market | 3.7% |
Stable Share Price: 2496's share price has been volatile over the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2496's weekly volatility has increased from 9% to 16% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 114 | Pengfei Zhou | www.yzybio.com |
Wuhan YZY Biopharma Co., Ltd., a biotechnology company, develops bispecific antibody-based therapies for the treatment of cancer, cancer-related complications, and age-related eye diseases. It develops various product candidates for the treatment of malignant ascites, malignant pleural effusion, solid tumors, pancreatic cancer, hepatocellular carcinoma and other advanced solid tumors, small cell lung cancer, relapsed/refractory multiple myeloma, and HER2-positive solid tumors; and covid 19 indication, as well as wAMD, DME, and other ocular neovascularization-related diseases. The company was founded in 2010 and is based in Wuhan, China.
Wuhan YZY Biopharma Co., Ltd. Fundamentals Summary
| 2496 fundamental statistics | |
|---|---|
| Market cap | HK$1.54b |
| Earnings (TTM) | -HK$195.54m |
| Revenue (TTM) | HK$8.59m |
179.1x
P/S Ratio-7.9x
P/E RatioIs 2496 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2496 income statement (TTM) | |
|---|---|
| Revenue | CN¥8.07m |
| Cost of Revenue | CN¥0 |
| Gross Profit | CN¥8.07m |
| Other Expenses | CN¥191.60m |
| Earnings | -CN¥183.53m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.95 |
| Gross Margin | 100.00% |
| Net Profit Margin | -2,275.35% |
| Debt/Equity Ratio | 241.0% |
How did 2496 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 06:39 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Wuhan YZY Biopharma Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|